Learn More
PURPOSE Preclinical studies suggest that treatment with a selective cyclo-oxygenase-2 (COX-2) inhibitor may augment the antitumor effects of chemotherapy. In this study, patients with non-small-cell(More)
7137 Background: Current 2nd-line treatment options for pts with advanced stage NSCLC are limited. New, more effective, and less toxic agents/combinations are thus needed for treating NSCLC in the(More)
PURPOSE Trials combining irinotecan/docetaxel and irinotecan/gemcitabine in second-line treatment of non-small-cell lung cancer (NSCLC) have yielded promising results. Preliminary data suggested that(More)